Rhythm Pharmaceuticals Inc
$ 105.70
1.02%
04 Dec - close price
- Market Cap 6,982,594,000 USD
- Current Price $ 105.70
- High / Low $ 107.57 / 102.76
- Stock P/E N/A
- Book Value 2.23
- EPS -3.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.86 %
- 52 Week High 116.00
- 52 Week Low 45.91
About
Rhythm Pharmaceuticals, Inc. is a Boston-based biopharmaceutical innovator focused on developing groundbreaking therapies for rare genetic obesity disorders. The company's flagship product, Imcivree (setmelanotide), targets the underlying biological mechanisms of severe obesity associated with specific genetic conditions, providing critical treatment options for an underserved patient demographic. Leveraging its expertise in melanocortin system research, Rhythm is poised to expand its pipeline, further enhancing patient outcomes and quality of life, and reinforcing its leadership position at the intersection of genetic medicine and metabolic health.
Analyst Target Price
$127.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-05 | 2025-05-05 | 2025-02-20 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 | 2023-05-02 | 2023-03-01 |
| Reported EPS | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.69 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 | -0.75 |
| Estimated EPS | -0.6874 | -0.67 | -2.16 | -0.73 | -0.8 | -0.71 | -2.16 | -0.7 | -0.74 | -0.79 | -0.73 | -0.81 |
| Surprise | -0.1326 | -0.08 | 1.35 | 0.01 | 0.07 | 0.02 | -0.19 | 0 | -0.02 | -0.03 | -0.19 | 0.06 |
| Surprise Percentage | -19.2901% | -11.9403% | 62.5% | 1.3699% | 8.75% | 2.8169% | -8.7963% | 0% | -2.7027% | -3.7975% | -26.0274% | 7.4074% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2025-10-17 13:01:23
Rhythm Pharmaceuticals, Inc. reached a new 52-week high of $106.84 on October 14, 2025, demonstrating strong performance with a 156.52% stock price increase over the past year and an exceptional return on equity of 1,528.51%. The small-cap company, with a market capitalization of approximately $6.63 billion, significantly outperformed the S&P 500 despite a high debt-to-equity ratio and no dividends. This milestone reflects its robust standing in the pharmaceuticals and biotechnology sector.
2025-10-17 04:09:39
Rhythm Pharmaceuticals, Inc. reached a new 52-week high of $109.68 on October 15, 2025, marking a 166.64% increase over the past year. The company, with a market capitalization of $6,627 million, despite being currently loss-making, showcases impressive financial metrics like a 1,528.51% return on equity. This performance highlights dynamism within the biotechnology sector.
2025-10-15 17:40:29
The article reports that Rhythm Pharmaceuticals stock reached an all-time high of 106.72 USD. However, there is an application error on the website preventing the full article content from loading.
2025-10-15 10:45:34
This article reports that Rhythm Pharmaceuticals stock reached an all-time high of $106.72 USD. However, the full content of the news article is not displayed due to an application error on the website.
2025-10-14 18:44:39
The article reports that Rhythm Pharmaceuticals stock reached an all-time high of 106.72 USD. However, due to a client-side application error, the full article content is not available.
2025-10-14 16:14:44
Hunter Smith, CFO of Rhythm Pharmaceuticals, discusses the unique challenges and responsibilities of his role, particularly in translating complex pharmaceutical information for investors. He highlights the differences between being a CFO at a large corporation versus a small company, emphasizing the need to wear many hats and the impact of specific pharma regulations on financial prospects. Smith also touches on the financial implications of manufacturing in Europe and selling in the US for his company.
